Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CTSL | P07711 | 5/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494159 | 0.86 | CTSS (0.42) | CTSSCTSLCTSKCTSB | |
| SCHEMBL6528739 | 0.82 | CTSS (0.54) | CTSSCTSLCTSKCTSB | |
| SCHEMBL5946020 | 0.81 | KCNA3 (0.42) | RXFP1SMN1; SMN2NPC1RAB9AFBP1 | |
| SCHEMBL5946029 | 0.81 | KCNA3 (0.42) | RXFP1SMN1; SMN2NPC1RAB9AFBP1 | |
| SCHEMBL5366946 | 0.79 | CTSS (0.53) | CTSSCTSLCTSKCTSB | |
| SCHEMBL14383667 | 0.79 | CTSS (0.53) | CTSSCTSLCTSKCTSB | |
| SCHEMBL14383668 | 0.76 | CTSS (0.46) | CTSSCTSLCTSKCTSB | |
| SCHEMBL5368517 | 0.76 | CTSS (0.46) | CTSSCTSLCTSKCTSB | |
| SCHEMBL5360338 | 0.75 | CTSS (0.48) | CTSSCTSL | |
| SCHEMBL5372284 | 0.75 | CTSS (0.48) | CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936606-B2 | Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | claimed |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | claimed |
| US-6936606-B2 | Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | CTSS 1/4885CTSL 8/4885CTSK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.